The week in pharma: action, reaction and insight – week to May 31, 2024
By Barbara Obstoj-Cardwell. Editor
Cambridge, USA-based Agios Pharmaceuticals last week agreed to sell its royalty rights on Servier’s sales of vorasidenib for up to $1.1 billion to Royalty Pharma. US pharma giant Merck & Co last Wednesday announced its intention to acquire EyeBio for up to $3 billion along with its ophthalmology pipeline. On the research front, biotech Insmed announced positive Phase III results for its bronchiectasis candidate brensocatib. Human Immunology Biosciences (HI-Bio), the subject of a $1.8 billion takeover bid from Biogen, released positive results for its CD38 antibody felzartamab in the treatment of IgA nephropathy. Also, Gilead Sciences released Ph III trial results for Trodelvy in bladder cancer, which failed to meet its primary endpoint.
Vorasidenib $1B Transaction adds $10/share value for Agios
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze